MỘT SỐ YẾU TỐ LIÊN QUAN ĐẾN TĂNG NỒNG ĐỘ GLUCOSE HUYẾT TƯƠNG Ở BỆNH NHÂN UNG THƯ SAU HÓA TRỊ TẠI BỆNH VIỆN TRUNG ƯƠNG THÁI NGUYÊN

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả:

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Khoa học và Công nghệ - Đại học Thái Nguyên, 2020

Mô tả vật lý: tr.274-279

Bộ sưu tập: Báo, Tạp chí

ID: 302113

Thêm vào giỏ Liên kết toàn văn

Nghiên cứu nhằm phân tích một số yếu tố liên quan đến tăng nồng độ glucose huyết tương ở các bệnh nhân ung thư sau hóa trị tại Trung tâm Ung bướu Bệnh viện Trung ương Thái Nguyên. Bằng phương pháp mô tả, theo dõi dọc 266 bệnh nhân (BN) ung thư (UT) được hóa trị ít nhất 3 chu kỳ hóa chất trở lên. Kết quả cho thấy trước hóa trị, sau hóa trị chu kỳ 3 (CK3), nồng độ glucose tương ứng là 4,97±0,45 mmol/L, 5,33±0,99 mmol/L, với sự khác biệt có ý nghĩa thống kê p<
0,001. Sau CK3, tỷ lệ tăng glucose huyết tương ở nhóm BN UT đại tràng
nhóm BN UT điều trị bằng 5 fluouracil (5FU)
nhóm BN UT điều trị bằng phác đồ FOLFOX cao hơn có ý nghĩa so với nhóm BN UT vú
nhóm BN UT điều trị bằng cyclophosphamid
nhóm BN UT điều trị bằng phác đồ AC, sự khác biệt có ý nghĩa thống kê tương ứng (OR: 2,31
95% CI: 1,39-3,87
p<
0,01)
(OR: 2,15
95% CI: 1,28-3,61
p<
0,01)
(OR: 2,06
95% CI: 1,21-3,48
p<
0,01). Không có sự khác biệt có ý nghĩa thống kê về tỷ lệ tăng glucose huyết tương theo giai đoạn UT cũng như theo chỉ số khối cơ thể. Kết quả nghiên cứu cho thấy có tăng nồng độ glucose huyết tương sau hóa trị
nồng độ glucose huyết tương thay đổi sau hóa trị khác nhau theo loại UT, loại hóa chất cũng như theo phác đồ điều trị.This study aims to analyze some factor related to hyperglycemia in cancer patients in Thai Nguyen National Hospital. By a longitudinal study method of 266 cancer patients were treated at least 3 cycles of chemotherapy. The results show that prechemotherapy, after the 3rd cycle, the mean concentration of plasma glucose levels respectively were 4.97±0.45 mmol/L, 5.33±0.99 mmol/L, 5.44±1.12 mmol/L, with statistically significant differences. After the 3rd cycle, the prevalence of hyperglycemia in patients with colon cancer, in patients treated with 5FU, in patients treated with FOLFOX regimen were higher than in patients with breast cancer, in patients treated with cyclophosphamid, in patients treated with AC regimen, with respectively statistically significant differences (OR: 2.31
95% CI: 1.39-3.87
p<
0.01)
(OR: 2.15
95% CI: 1.28-3.61
p<
0.01)
(OR: 2.06
95% CI: 1.21-3.48
p<
0.01). Increased plasma glucose levels after chemotherapy. Plasma glucose levels changed differently by tumor types chemotherapeutic agents and regimens. After the 3rd cycle, the prediabetes, diabetes were 19.9% and 3.4%.

1.

Tạo bộ sưu tập với mã QR